Browse MYH13

Summary
SymbolMYH13
Namemyosin, heavy chain 13, skeletal muscle
Aliases MyHC-eo; extraocular muscle myosin heavy chain; extraocular myosin heavy chain; myosin, heavy polypeptide 13 ......
Chromosomal Location17p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm, myofibril. Note=Thick filaments of the myofibrils.
Domain PF00063 Myosin head (motor domain)
PF02736 Myosin N-terminal SH3-like domain
PF01576 Myosin tail
Function

Fast twitching myosin mediating the high-velocity and low-tension contractions of specific striated muscles.

> Gene Ontology
 
Biological Process GO:0003012 muscle system process
GO:0006936 muscle contraction
GO:0009267 cellular response to starvation
GO:0009991 response to extracellular stimulus
GO:0031667 response to nutrient levels
GO:0031668 cellular response to extracellular stimulus
GO:0031669 cellular response to nutrient levels
GO:0042594 response to starvation
GO:0071496 cellular response to external stimulus
Molecular Function GO:0000146 microfilament motor activity
GO:0003774 motor activity
GO:0003779 actin binding
GO:0005516 calmodulin binding
Cellular Component GO:0005859 muscle myosin complex
GO:0015629 actin cytoskeleton
GO:0016459 myosin complex
GO:0016460 myosin II complex
GO:0030016 myofibril
GO:0032982 myosin filament
GO:0043292 contractile fiber
GO:0044449 contractile fiber part
> KEGG and Reactome Pathway
 
KEGG hsa04530 Tight junction
Reactome R-HSA-199991: Membrane Trafficking
R-HSA-1445148: Translocation of GLUT4 to the plasma membrane
R-HSA-5653656: Vesicle-mediated transport
Summary
SymbolMYH13
Namemyosin, heavy chain 13, skeletal muscle
Aliases MyHC-eo; extraocular muscle myosin heavy chain; extraocular myosin heavy chain; myosin, heavy polypeptide 13 ......
Chromosomal Location17p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between MYH13 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolMYH13
Namemyosin, heavy chain 13, skeletal muscle
Aliases MyHC-eo; extraocular muscle myosin heavy chain; extraocular myosin heavy chain; myosin, heavy polypeptide 13 ......
Chromosomal Location17p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of MYH13 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolMYH13
Namemyosin, heavy chain 13, skeletal muscle
Aliases MyHC-eo; extraocular muscle myosin heavy chain; extraocular myosin heavy chain; myosin, heavy polypeptide 13 ......
Chromosomal Location17p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of MYH13 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)141201
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)6501
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)8701
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.90.255
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.0990.954
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-2.1540.342
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.370.676
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-2.1630.0794
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11121.8910.188
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.4590.499
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.4590.623
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1720.522
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of MYH13 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.15.91.21
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1031033.3-23.30.423
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.412.3-4.90.722
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.413.6-6.20.495
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211714.311.82.51
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86033.3-33.30.165
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131123.1023.10.223
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 382715.8015.80.037
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221327.3027.30.0645
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 1113023.1-23.10.223
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 512025-250.515
Summary
SymbolMYH13
Namemyosin, heavy chain 13, skeletal muscle
Aliases MyHC-eo; extraocular muscle myosin heavy chain; extraocular myosin heavy chain; myosin, heavy polypeptide 13 ......
Chromosomal Location17p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MYH13. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolMYH13
Namemyosin, heavy chain 13, skeletal muscle
Aliases MyHC-eo; extraocular muscle myosin heavy chain; extraocular myosin heavy chain; myosin, heavy polypeptide 13 ......
Chromosomal Location17p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MYH13. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MYH13.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolMYH13
Namemyosin, heavy chain 13, skeletal muscle
Aliases MyHC-eo; extraocular muscle myosin heavy chain; extraocular myosin heavy chain; myosin, heavy polypeptide 13 ......
Chromosomal Location17p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MYH13. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolMYH13
Namemyosin, heavy chain 13, skeletal muscle
Aliases MyHC-eo; extraocular muscle myosin heavy chain; extraocular myosin heavy chain; myosin, heavy polypeptide 13 ......
Chromosomal Location17p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of MYH13 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolMYH13
Namemyosin, heavy chain 13, skeletal muscle
Aliases MyHC-eo; extraocular muscle myosin heavy chain; extraocular myosin heavy chain; myosin, heavy polypeptide 13 ......
Chromosomal Location17p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between MYH13 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolMYH13
Namemyosin, heavy chain 13, skeletal muscle
Aliases MyHC-eo; extraocular muscle myosin heavy chain; extraocular myosin heavy chain; myosin, heavy polypeptide 13 ......
Chromosomal Location17p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting MYH13 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.